To print: Select File and then Print from your browser's menu

Title: Penile, Scrotal Cancer Still Linked To Psoralen Plus Ultraviolet-A Psoriasis Treatment

URL: http://www2.us.elsevierhealth.com/scripts/om.dll/serve?acti
ion=searchDB&searchDBfor=art&artType=abs&id=a124618&nav=abs

J Am Acad Dermatol 2002;47:33-9. "The persistent risk of genital tumors among men treated with psoralen plus ultraviolet A (PUVA) for psoriasis"
07/23/2002 10:31:18 AM
By Mark Greener

Men who undergo treatment for psoriasis with psoralen plus ultraviolet A (PUVA) are at increased risk of developing genital squamous cell carcinomas (SCCs) compared to the general population, despite measures to reduce the hazard. Researchers from the Beth Israel Deaconess Medical Center, Boston, United Sates, performed a prospective cohort study that enrolled 892 men with psoriasis who first received PUVA between 1975 and 1976. Of these, 24 men - 2.7 percent of the total - developed 51 genital neoplasms. Compared to the general Caucasian population, the risk that men undergoing PUVA would develop invasive penile and scrotal SCCs rose 52.6-fold. Exposure to high doses of PUVA as well as topical tar and ultraviolet B was associated with an increased incidence of genital SCCs. The increase was 4.5 fold compared with those who received low-doses. The authors noted that the PUVA is now used less commonly and genital shielding is more widely employed than was the case several years ago. Nevertheless, men treated using PUVA still show dose-dependent increases in the risk of developing genital SCCs. In particular, men exposed to high-doses of PUVA and topical tar plus ultraviolet B are especially likely to develop genital SCCs.

http://www2.us.elsevierhealth.com/scripts/om.dll/serve?acti
ion=searchDB&searchDBfor=art&artType=abs&id=a124618&nav=abs

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.